Depressive symptoms · people with a primary brain tumour
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with a primary brain tumour
1 finding from 1 review
Quality of life EORTC QLQ‐BN 20 · people with a primary brain tumour
1 finding from 1 review
Fatigue · people with a primary brain tumour
2 findings from 1 review
Cognition Trail Making Test A · people with a primary brain tumour
1 finding from 1 review
Cognition Trail Making Test B · people with a primary brain tumour
1 finding from 1 review
Partial renal remission · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Stable kidney function · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Complete renal remission · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
Cumulative incidence of atopic disease at 2.5 years old · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Diagnosis of IgE‐mediated food allergy · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Diagnosis of asthma · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Diagnosis of anaphylaxis (not vaccine associated) · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
All‐cause serious adverse events · the promotion of growth and prevention of infections in infants less than six months of age
Efficacy and safety of a first dose of whole‐cell pertussis vaccine showed no clear difference in all‐cause serious adverse events compared with a first dose of acellular pertussis vaccine (moderate certainty).
1 finding from 1 review
Diagnosis of encephalopathy · the promotion of growth and prevention of infections in infants less than six months of age
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
1 finding from 1 review